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Does the novel coronavirus use the ocular surface as an
entrance into the body or as an infection site?
O novo coronavírus usa a superfície ocular como porta de entrada
no corpo ou como local de infecção?
Remzi Karadag1
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ABSTRACT | This study attempts to review whether the coronavirus
disease-2019 (COVID-19) is transmitted through the ocular
surface and examine the symptoms and signs of ocular disease.
Considering that COVID-19 is transmitted by airborne droplets
and close contact with infected individuals, we will also review
the conditions to which eye clinics and ophthalmologists should
pay attention to prevent the transmission of the disease. Although
some researchers have argued that COVID-19 transmission cannot
occur through the ocular surface, most of them are of the opinion
that the ocular surface is a potential pathway of transmission.
Until date, ocular signs and symptoms have been rarely reported
in the COVID-19 patients. However, there are case reports of
conjunctivitis as the first, and rarely, the only clinical symptom
of the disease. In addition, low coronavirus RNA positivity can be
detected in the ocular surface samples. Further laboratory and
clinical investigations are needed to ascertain whether the ocular
surface is one of the potential transmission pathways through
which severe acute respiratory syndrome-coronavirus 2 can gain
entry into the human body.
Keywords: Coronavirus infections; Coronavirus; COVID-19;
SARS-CoV-2; Conjunctivitis; Eye manifestations; Disease transmission, infectious
RESUMO | Rever se o COVID- 19 é transmitido através da su
perfície ocular e seus sintomas e sinais na doença ocular. Dado
que o COVID-19 é transmitido por gotículas de ar e contato
próximo, também analisaremos, também, as condições às quais os
oftalmologistas e as clínicas oftalmológicas devem prestar atenção
a fim de evitar a transmissão da doença. Embora alguns autores
tenham argumentado que a transmissão de COVID-19 não pode

Submitted for publication: July 16, 2020
Accepted for publication: September 29, 2020
Funding: This study received no specific financial support.
Disclosure of potential conflicts of interest: None of the authors have any potential
conflicts of interest to disclose.
Corresponding author: Remzi Karadag.
E-mail: drrkaradag@yahoo.com

ocorrer através da superfície ocular, a maioria dos autores acredita
que a superfície ocular é uma via potencial de transmissão. Até
à data, foram notificados, muito raramente, sinais e sintomas
oculares em doentes com COVID- 19. No entanto, há relatos de
casos de conjuntivite como sendo, raramente, o primeiro e único
sintoma clínico da doença. Além disso, a baixa positividade do
RNA coronavírus pode ser detectada nas amostras da superfície
ocular. São necessárias mais investigações clínicas laboratoriais
sobre se a superfície ocular é uma das vias de transmissão através
das quais o SARS-COV-2 penetra no corpo humano.
Descritores: Infecções por coronavirus; Coronavirus; COVID-19;
SARS-CoV-2; Conjuntivite; Manifestações oculares; Transmissão
de doença infecciosa

INTRODUCTION
The coronavirus disease 2019 (COVID-19), which
was first reported in the city of Wuhan in the Hubei Province of the People’s Republic of China in 2019, is caused by severe acute respiratory syndrome-coronavirus-2
(SARS-CoV-2)(1-4). COVID-19 was declared a pandemic
by the World Health Organization on March 11, 2020.
As of June 2, 2020, there are 6,382,952 confirmed cases
and 380,318 fatalities worldwide(5).
Although COVID-19 mainly affects the respiratory
system, it may also involve other organ systems such
as the gastrointestinal, olfactory, neurological, renal,
cardiovascular, and ocular systems(1,2).
This article aims to review the methods of contamination as well as the clinical and laboratory ocular findings
of COVID-19 and highlight the currently available eye
protection methods.
Severe acute respiratory syndrome-coronavirus 2

Coronaviruses (CoVs) are known to affect a wide range
of birds and mammals, including pets such as cats (feline)
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and dogs (canine)(6,7). CoVs are zoonotic pathogens capable of mutating, which facilitates their transmission from
animals to humans(8).
SARS-CoV-2, Middle East respiratory syndrome-co
ronavirus (MERS-CoV), and severe acute respiratory
syndrome-coronavirus (SARS-CoV) belong to the family
of beta Coronaviridae which are enveloped positive-stran
ded ribonucleic acid (RNA) viruses. There are four
groups of CoVs, namely alpha, beta, gamma, and delta.
While the alpha and beta coronaviruses primarily affect
the respiratory, gastrointestinal, and central nervous
systems of human and mammalian hosts, gamma and
delta coronaviruses are mostly avian pathogens(1-3).
Coronaviruses are capable of interspecies transmission
and cause diseases ranging from the common cold to the
more severe MERS and SARS in humans.
CONTAMINATIONS
Frequent methods of contamination

The main routes of transmission for human coronaviruses are thought to be respiratory droplets generated by
infected individuals and direct contact with virus-contaminated fomites. Recently, SARS-CoV and SARS-CoV-2
have also been detected in stool and urine samples,
making the fecal-oral route a possible means of transmission for the viruses. Additionally, transconjunctival
contamination has been hypothesized since the main
contamination route of SARS-CoV-2 is trans mucosal(1-4).
The virus can remain viable on diverse surfaces for
up to 72 hours with different degrees of infectivity(1). The
median incubation period is 5.1 days and ranges from
1 to 14 days(1-4).
The coronavirus binds to specific receptors on host
cells through its S protein and enters them. Angiotensin-converting enzyme-2 (ACE-2) is a cellular receptor
that is utilized by SARS-CoV-2 to enter the cell. The entry
receptor of SARS-CoV, HCoV-NL63, and SARS-CoV-2
is ACE2, which is highly expressed in the human lung
alveolar epithelial cells, enterocytes of the intestinal
system, and the proximal tubular cells of the kidney(9,10).
Viral entry is also associated with type II transmembrane serine protease (TMPRSS2) activity. Although
it has been reported that ACE-2 is not present in the
upper airway, ACE-2 and TMPRSS-2 have been detected
in the epithelial cells of the upper and lower airways
by immunohistochemical methods. Specifically, the
gene expression patterns of these two receptors have
demonstrated that alveolar type II epithelial cells are

largely involved(9,10). Kam et al.(11) reported that entry
into human B cell lines involves a FcγRII-dependent
and ACE2-independent mechanism, showing that
antibody-dependent enhancement (ADE) of viral entry
is another potential target cell entryway of SARS-CoV.
ADE occurs when a virus-antibody complex interacts
with Fc Receptor or complement to begin viral uptake or
alternatively when antibodies stimulate structural changes in envelope glycoproteins that are needed for virus-cell
membrane fusion(11). In another study, Yang et al.(12)
showed that a civet cat type of SARS-CoV demonstrated
enhanced entry into a human renal epithelial cell-line in
the presence of human monoclonal antibodies against a
human type of SARS-CoV spike.
Transmission via the ocular surface

Since the main transmission route of SARS-CoV-2 is
trans mucosal, ocular surface transmission is one of the
contamination pathways that has been speculated by
many researchers. Anatomically, the ocular surface carries a risk of exposure to infectious droplets and fomites during close contact with patients or contaminated
hands. The results from the limited number of studies
on this subject remain controversial(9,13-17).
Conjunctivitis and other ocular complications have
not been reported in patients with SARS-CoV and
MERS-CoV disease, while few cases with SARS-CoV-2
infection and only four cases with HCo-NL63 infection
have been reported to be associated with conjunctivitis(9,13-17). Therefore, ocular manifestations are rarely
seen in human CoV infection(8,10,13-16).
Recently, the presence of human CoV RNA in ocular
surface samples was tested by reverse transcription-po
lymerase chain reaction (RT-PCR) in SARS and COVID-19
patients; however, the positivity rate was exceedingly
low(4,16-20). Deng et al. reported that no SARS-CoV-2 could
be detected by RT-PCR in 114 ocular surface samples
obtained from patients with COVID-19 pneumonia(21).
Additionally, Lange et al. evaluated the mRNA expression pattern of the SARS-CoV-2 receptor ACE-2 and
its cofactors in 38 human conjunctival samples. The
findings indicated that the SARS-CoV-2 receptor ACE-2
and other auxiliary molecules are not substantially expressed in conjunctival samples at the mRNA or protein
levels(22). Because of the rarity of the ocular manifestations and the extremely low positivity rate of human
CoV RNA test by RT-PCR in ocular surface samples,
ocular surface transmission is not considered by some
Arq Bras Oftalmol. 2022;85(1):92-8
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authors to be a prime contamination route of human
CoV infection(4,13-17).
The human eye has its own intraocular renin-angiotensin system, which exists not only on the ocular
surface but also inside the eye (trabecular meshwork,
aqueous humor, iris, ciliary body, and retina). Similar
to other cells in the body, ACE2 and TMPRSS2 are currently believed to be important factors in ocular surface
cell entry(23-26). Previous studies elicited significant gene
expression of the ACE-2 receptor in the ocular surface
together with TMPRSS2 protein. The co-expression of
ACE-2 and TMPRSS2 in the corneal limbal cells verifies the high affinity of this tissue for SARS-CoV-2 and
its existence in tears(23-26). Although the expression of
ACE-2 was detected in ocular surface epithelial cells,
its expression in the corneal and conjunctival epithelial
cells was found to be lower than that in the lung and
kidney cells(10,25,26).
The nasolacrimal system provides an anatomic
connection between the ocular surface and the upper
respiratory tract. When a drop is instilled into the eye,
even though some of it is absorbed by the cornea and
the conjunctiva, most of it is drained into the nasal cavity through the nasolacrimal canal and is subsequently
transferred to the upper respiratory or the gastrointestinal tract(27). The presence of SARS-CoV-2 in tears has also
been reported. Hence, the passage of the virus from the
eye to the nasopharynx via a patent nasolacrimal canal
is possible regardless of the presence of ACE2 receptors
in the cornea and conjunctiva(28).
Loon et al. detected SARS-CoV in the tear samples
of 36 consecutive suspects during the SARS epidemic in
2004(14). SARS-CoV was present in the tears only in three
of the eight confirmed SARS cases sampled in the early
phase of their illness. In other cases, who were in the later
phase of the illness, the tear samples were SARS-CoV
negative(18). Conjunctival swab and sputum samples of
30 COVID-19 patients with conjunctivitis were analyzed
by PCR for SARS-CoV-2 in a prospective study by Xia et
al.(17). Each patient was sampled twice, with an interval
of 2-3 days. Only two conjunctival and tear samples in
the eye with conjunctivitis were positive, while 55 of
the 60 sputum samples showed positive PCR results for
SARS-CoV-2(17). Previous studies revealed the presence
of SARS-CoV in patients’ tears and MERS-CoV RNA in
camels’ conjunctival swabs in the early stage of the
disease using PCR. Both of these viruses are members
of the same Coronaviridae family to which SARS-CoV-2
belongs(18,29).
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Chen et al.(30) detected SARS-CoV-2 in the conjunctival swabs of a patient with confirmed COVID-19 and
bilateral conjunctivitis 13 days after the onset of the illness. Viral RNA was found in their patient’s conjunctiva
for at least 5 days. However, the authors stated that the
viral RNA levels in conjunctival specimens were significantly lower than those in airway samples(30). Wu et al.(31)
retrospectively evaluated 38 patients with either confirmed COVID-19 or highly suspected to have the disease.
They reported that the RT-PCR results were positive for
SARS-CoV-2 in 28 nasopharyngeal swabs but only in 2
conjunctival swabs although 12 of their patients had
ocular manifestations. The authors stated that the low
positivity rates of the conjunctival swab results might
have been due to the fact that only one sample was taken
from each patient’s eye(31).
Deng et al.(32) showed that SARS-CoV-2 infection
could be induced by ocular surface inoculation in an
experimental animal model using macaques. Although
the researchers detected the virus in conjunctival swabs
only on the first day after inoculation, they continued
to detect it in nasal and throat swabs 1-7 days after the
inoculation. Their findings demonstrated that the viral
load in the airway mucosa was much higher than that
in the ocular surface. They euthanized and necropsied
one of the conjunctival inoculated-animals and found
that the virus had spread to the nasolacrimal system and
ocular tissue, nasal cavity, pharynx, trachea, tissues in
the oral cavity, tissues in the lower-left lobe of the lung,
inguinal and perirectal lymph node, stomach, duodenum, cecum, and ileum. They also found a specific IgG
antibody, indicating that the animal was infected with
SARS-CoV-2 via the ocular surface route(32).
The remarkably low positivity rate of SARS-CoV-2
in the tears and conjunctival secretions of COVID-19
patients when tested by RT-PCR may be explained
as follows: First, the sensitivity of the currently used
RT-PCR test still needs to be improved because previous
studies have reported that the sensitivity of the test is
only 50%-60%(19,27). Second, the time of ocular surface
sample collection is likely to be in the later phase of the
infection unless the patient exhibited ocular symptoms
at the onset of infection. Previous studies demonstrated that samples with positive PCR results were mostly
obtained within 7 days of the onset of infection. Since
the ocular findings are infrequent in patients with
SARS-CoV-2 RNA, it is highly likely that samples were
either not taken at all or not taken at the appropriate
time. Third, in current clinical practice, although some
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suspected COVID-19 cases often undergo 2-3 repeated
tests of nasopharyngeal swabs before obtaining positive
results(14), the same number of repeated tests are not usually
performed for ocular surface samples. Additionally, because the respiratory symptoms of COVID-19 infection
are often severe and even fatal, mild eye symptoms are
not prioritized, and therefore, ocular surface swabs may
not be tested. Fourth, SARS-CoV-2 may originate from
fomites and be transmitted to the ocular surface via
splashed droplets or via direct contact with contaminated hands. The majority of these viruses are transmitted
through the lacrimal canal to the nasopharynx owing to
the washing effect of the tears(1,32). Therefore, in individuals with ocular surface contact, the probability of a
positive test may increase when tears and conjunctival
samples are obtained at the earliest after the contact
occurred(33). Fifth, antimicrobial agents such as lactoferrin and secretory IgA, in addition to the washing effect
of tears, reduce the viral load in the ocular surface(27,34).
Sixth, some swabs used in specimen sampling (calcium
alginate swabs or swabs with wooden shafts) may contain substances that inactivate viruses and inhibit PCR
testing. Moreover, topical anesthetics, which may affect
the survival of the viruses, are not recommended while
collecting ocular surface samples(35). Lastly, insufficient
tear collection during sampling may have some effect
on the positivity rate of the PCR test(1,34). In the light of
previous publications, most authors believe that the
ocular surface may be a potential but unlikely route of
transmission for the coronavirus(18,29-32).
CLINICAL MANIFESTATIONS
The systemic clinical manifestations of COVID-19
include fever, chills, fatigue, muscle pain, headache,
sore throat, loss of taste or smell, and respiratory distress. The clinical spectrum of the disease varies from
asymptomatic and mild forms to respiratory failure that
requires intensive care unit support, which may at times
progress to sepsis, septic shock, and multiple organ dysfunction syndromes(36). Up to 50% of the positive cases
may be asymptomatic; thus, approximately 80% of the
patients are either asymptomatic or show only mild
symptoms(36,37). In some cases, bilateral irregular shadows
or frosted glass opacities have been demonstrated on
the chest computed tomographic scans(36).
The most common ocular manifestation of SARS-CoV-2
is mild conjunctivitis that presents with a follicular
reaction, hyperemia, chemosis, watery discharge, and

mild eyelid edema(1). Although the prevalence of ocular
manifestations among the COVID-19 patients has been
reported to be <5% in many studies(1,14,28), it has been
demonstrated to be as high as 31.6% in one study(31).
The reason for the low rate of conjunctivitis reported
by most studies may be the fact that mild conjunctivitis
does not receive sufficient attention and is not well
documented in patients presenting with a complex and
life-threatening clinical scenario. Moreover, patients
with conjunctivitis symptoms that are associated with
mild systemic symptoms often quarantine themselves
and may never undergo a medical evaluation. Interestingly, only 5% of the conjunctival swabs were positive
for SARS-CoV-2 in a case series in which 31.6% of the
patients had conjunctivitis(31).
Wu et al.(31) retrospectively evaluated the results
of 38 patients confirmed or highly suspected to have
COVID-19. Among them, 12 had various ocular manifestations, including epiphora, conjunctival congestion,
or chemosis. Such ocular findings were generally noted
in patients with more serious systemic manifestations(31).
Chen et al.(30) reported the case of a patient with
confirmed COVID-19 and bilateral conjunctivitis. They
found that the ocular findings occurred 13 days after
the onset of systemic illness(30). A case of pseudomembranous and hemorrhagic conjunctivitis was documented(38). Salducci et al.(39) reported a case of a person who
had traveled from Italy to Japan with COVID-19 and
developed severe viral conjunctivitis characterized by
redness, irritation, and swelling in both eyes along with
serous secretions, conjunctival chemosis, and pseudomembranes(39).
As of now, there are detailed reports of five COVID-19
patients who demonstrated conjunctivitis as the initial
finding of a systemic COVID-19 infection(13,20,31,39,40). Two
of them were health workers, i.e., a pulmonologist(20)
and an anesthesiologist(13). The former, who had visited
Wuhan in January 2020 reported that he was infected
with SARS-CoV-2 despite being fully gowned with a
protective suit and an N95 mask. Conjunctivitis was
his first clinical manifestation, followed by catarrhal
symptoms and fever a few hours later(20). Shortly after
this information was available, health care workers in
China were encouraged to use eye protection during
close contact with confirmed or suspected COVID-19
patients. The anesthesiologist who had conjunctivitis as
the initial COVID-19 symptom stated that she had worn
a surgical mask, cap, and gloves during patient care. Her
ocular manifestations developed after she had perforArq Bras Oftalmol. 2022;85(1):92-8
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med tracheal intubation for a patient with COVID-19.
She later developed fever and cough(13). The other three
patients with the initial symptom of conjunctivitis were
non-healthcare professionals(31,39,40). Even though all
five patients had obvious ocular manifestations, the
SARS-CoV-2 test was positive in ocular surface samples
in only two of them(13,20,31,39,40). Apart from these five patients, Stalinci and Battagliola reported five confirmed
COVID-19 cases in whom conjunctivitis was the sole finding and no other systemic symptoms were present(41).
Marinho et al. reported retinal OCT findings in
confirmed COVID-19 patients who did not exhibit any
ocular symptoms. All 12 patients in this series showed
hyper-reflective lesions at the level of ganglion cell and
inner plexiform layers prominently at the papillomacular bundles in both eyes, representing an inflammatory
response to the virus(42).
Given that conjunctivitis may be the first symptom
of COVID-19, the source of the disease may well be the
ocular surface(13,20,31,39,40). However, most authors believe
that the ocular surface is less likely to be the source of
tissue invasion and ocular infection. Further studies are
needed to resolve this issue.
PROTECTION
As is evident from the review, there is no consensus
among the authors regarding COVID-19 transmission
via the ocular surface, and the available data are mostly
based on anecdotal reports. However, since COVID-19
is a life-threatening disease, it is best to assume that it
is transmissible through the ocular surface until additional evidence is available. Therefore, all ophthalmology
departments and offices should take special precautions
during this pandemic to protect their doctors, staff
members, and patients. It is important to note that an
ophthalmologist contracted the disease after contact
with a glaucoma patient with subclinical COVID-19 and
later lost his life(43).
While most ocular disorders are not life-threatening,
sight-threatening conditions warrant attention. Cases of
ocular trauma, retinal detachment, acute angle-closure
glaucoma, severe infections such as keratitis, orbital cellulitis, or uveitis exacerbations, and acute posterior vitreous
detachment should be evaluated without any delay. If
patients need emergency surgery, it should be done under
local anesthesia if possible, and a COVID-19 test should
be performed if the patient has fever or other suspicious
symptoms. However, follow up examinations of slow-pro96
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gressing disorders such as cataract, chronic open-angle
glaucoma, or ptosis and procedures such as contact lens
refitting may be put off for a reasonable time(43).
The decision regarding intravitreal injections should
be considered on a case-by-case basis. While temporarily postponing injections for diabetic macular edema
and retinal branch vein occlusion might be acceptable,
treatment plans for wet-type age-related macular degeneration and central retinal vein occlusion should not
be altered(44).
Care for posterior uveitis patients is of special significance since there is a potential threat of vision loss if
the treatment is delayed. For newly diagnosed cases and
acute exacerbations of chronic diseases, the patients
may be treated with periocular steroid injections to
delay systemic steroid therapy as the latter could potentially increase the morbidity and mortality risk during a
pandemic. For patients in whom steroid treatment alone
may suffice, such as those with Behçet’s disease necessitating the use of antimetabolites, calcineurin inhibitors,
or biologic agents, dose lowering and periocular steroid
injections may be considered(45).
The number of appointments per day should be reduced, thereby allowing an adequate interval between
the patients. Those with non-urgent complaints who do
not have severe pain, vision loss, or photophobia may
be assessed through teleconsultation. Timely telephonic
or video consultations may avoid unnecessary visits by
proper triage(46).
All patients examined in an office should be questioned about possible COVID-19 symptoms such as fever,
cough, shortness of breath, or loss of smell and taste
along with possible contact with a COVID-19 patient.
Temperature measurements are recommended before
entering the examination room(43,46,47).
The patients confirmed or suspected to have COVID-19
should be examined in a separate room with a minimum
number of people in it. The patients must wear a mask
and disinfect their hands. The physicians should be in full
personal protective equipment, including gown, FFP2 or
FFP3 mask, goggles, and gloves. Handwashing with soap
and water for at least 20 seconds is crucial before and
after each examination. The room should be properly
ventilated after the examination, and the contact surfaces should be disinfected with 70% ethyl alcohol or the
equivalent(43).
The proximity between the patient and the physician
during slit-lamp examination makes ophthalmologists
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particularly vulnerable to SARS-CoV-2 contamination.
Transparent shields attached to the slit-lamp microscope,
in addition to the standard protective equipment, may
be helpful in avoiding the spread of aerosols. These
shields should be disinfected with 70% ethyl alcohol or
the equivalent after each examination(47).
Reusable examination tools such as tonometer,
A- and B-scan probes, and contact examination lenses
should be properly disinfected. Automatic phoropters
for refraction and indirect helmet ophthalmoscopes
for retinal examination are preferable as they enable
a distant examination. The top portion of the patient’s
mask may be fixated with a skin plaster to avoid fogging
of the oculars of the phoropter. Non-contact tonometer
should be located in a separate room to avoid aerosol
formation with the air puff(44). Additionally, particular
attention should be paid to washing hands frequently
with soap and water or the equivalent(43-47).
Although some authors have argued that COVID-19
transmission cannot occur through the ocular surface,
the general opinion of most authors is that the ocular
surface is a potential pathway of transmission. Since COVID-19 is a life-threatening disease, it is safe to assume
that it may be transmitted through the ocular surface
until sufficient laboratory and clinical data are available
to prove otherwise. To date, ocular signs and symptoms
have been rarely reported in COVID-19 patients. However, there are case reports of conjunctivitis as the first,
and occasionally, the only clinical manifestation of the
disease. Since COVID-19 is transmitted through droplets
and by close contact with infected individuals and because ophthalmologists are in close proximity to their
patients during the examination, they are at an increa
sed risk for this infection. Therefore, patients, techni
cians, and physicians should use personal protective
equipment during the process. Protective glasses, face
mask/shield, and shield attached to a biomicroscope
should be used to prevent conjunctival transmission.
Moreover, the devices and tools used during the examination must be cleaned upon contact with a suspect.
Further laboratory and clinical investigations are needed
to ascertain whether the ocular surface is one of the
transmission pathways through which SARS-CoV-2 enters the human body.
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